HCC expressing cytokeratin (CK) 7 or CK19 are considered cholangiocyte phenotypes with highly aggressive behavior that can stimulate HCC proliferation, metastasis, and sorafenib therapy resistance [3, 4]. The gene discussed is KRT19; the disease is hepatocellular carcinoma.